Technical Analysis for CRY - CryoLife, Inc.
|Grade||Last Price||% Change||Price Change|
CRY closed up 0.55 percent on Monday, May 22, 2017, on 50 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Trend Table & Recent Alerts
|See historical CRY trend table...|
|Date||Alert Name||Type||% Chg|
|May 22||Narrow Range Bar||Range Contraction||0.00%|
|May 19||Stochastic Reached Oversold||Other||0.55%|
|May 18||NR7||Range Contraction||0.55%|
|May 18||Narrow Range Bar||Range Contraction||0.55%|
|May 18||1,2,3 Pullback Bullish||Bullish Swing Setup||0.55%|
|May 18||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.55%|
|May 16||Hammer Candlestick||Bullish||-3.42%|
|May 15||NR7||Range Contraction||-2.91%|
|May 15||NR7-2||Range Contraction||-2.91%|
|May 12||NR7||Range Contraction||-2.65%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLife's proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Is CRY a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CRY news...
|52 Week High||20.15|
|52 Week Low||11.35|
|200-Day Moving Average||17.5176|
|50-Day Moving Average||16.969|
|20-Day Moving Average||18.3675|
|10-Day Moving Average||18.655|
|Average True Range||0.5016|
|Chandelier Exit (Long, 3 ATRs)||17.8452|
|Chandelier Exit (Short, 3 ATRs)||16.8548|
|Upper Bollinger Band||19.7514|
|Lower Bollinger Band||16.9836|
|Percent B (%b)||0.49|
|MACD Signal Line||0.6067|